Skip to main content

Advertisement

Figure 5 | BMC Cancer

Figure 5

From: Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry

Figure 5

Overall Survival by Genotype. When calculated from the time of diagnosis, patients with wild-type GIST/SDH deficiencies or KIT exon 11 mutations did better than other types. The long survival times for wild-type GIST/SDH deficiencies in this series may reflect a high percentage of pediatric-type GIST patients. The relatively short survival time noted for PDGFRα mutations should be interpreted with caution given the small numbers and short follow-up.

Back to article page